Therapeutics News and Research

RSS

Pediatric dietary mobile game improved children’s short-term food choices

Rates of overweight and obesity in children are rising around the world, with serious long-term consequences for health and health care costs. In prior research, video and mobile games have helped children eat healthier and exercise more.

11 Feb 2021

Researchers find a way to measure key characteristics of proteins that bind to RNA

A team of Case Western Reserve University researchers has found a way to measure key characteristics of proteins that bind to RNA in cells--a discovery that could improve our understanding of how gene function is disturbed in cancer, neurodegenerative disorders or infections.

11 Feb 2021

Scientists present new outlook on latest trends in peptide drug discovery and development

Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development.

10 Feb 2021

Exposure to seasonal coronaviruses does not produce antibodies that protect against SARS-CoV-2

Past exposure to seasonal coronaviruses (CoVs), which cause the common cold, does not result in the production of antibodies that protect against the novel coronavirus SARS-CoV-2, according to a study led by Scott Hensley, PhD, an associate professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania.

10 Feb 2021

Researchers identify top-performing COVID-19 POC tests

After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified 5 direct (antigen/RNA) tests for detection of acute infection and 6 indirect (antibody) tests for detection of prior infection that meet the recently published World Health Organization (WHO) "desirable" Target Product Profile (TPP) criteria.

10 Feb 2021

MD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitors

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents - which target two of the most frequent KRAS mutations in cancer.

10 Feb 2021

Modified lipids target the body’s endocannabinoid system to regulate pain and inflammation

When modified using a process known as epoxidation, two naturally occurring lipids are converted into potent agents that target multiple cannabinoid receptors in neurons, interrupting pathways that promote pain and inflammation, researchers report.

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

Monoclonal antibodies are showing promise for improving outcomes for COVID-19 patients, but when a hospital is already beyond capacity, administering them can be a challenge.

10 Feb 2021

New study to evaluate the effectiveness of drugs on preventing COVID-19 progression

McMaster University researchers are leading a large international study to test drugs to treat COVID-19 patients.

9 Feb 2021

People with dementia found to have significantly increased risk for COVID-19

A study led by Case Western Reserve University researchers found that patients with dementia were at a significantly increased risk for COVID-19 - and the risk was higher still for African Americans with dementia.

9 Feb 2021

New nanoparticle-based drug boosts the body’s innate immune system to fight tumors

A new nanoparticle-based drug can boost the body's innate immune system and make it more effective at fighting off tumors, researchers at UT Southwestern have shown.

8 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

Study implicates disruption in prenatal neurogenesis in the development of ASDs

A new study of autism risk genes by UC San Francisco and UC Berkeley scientists implicates disruption in prenatal neurogenesis - a process in which specialized "progenitor" cells give rise to new brain cells - in the development of autism spectrum disorders (ASDs).

8 Feb 2021

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

A new study describes the use of DARPin (designed ankyrin repeat proteins) therapeutic agents, each of which contains three different DARPin domains within the same molecule.

8 Feb 2021

Could graphene be an effective antiviral platform against SARS-CoV-2?

The urgent need for novel therapeutics has spurred investigation into broad-spectrum inhibitors of viral infection and replication. A new study describes the antiviral activity of synthesized graphene platforms, pointing to new therapeutic approaches against this virus.

8 Feb 2021

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

New SARS-Cov-2 mutations could arise during chronic infection, say scientists

SARS-CoV-2 mutations similar to those in the B1.1.7 UK variant could arise in cases of chronic infection, where treatment over an extended period can provide the virus multiple opportunities to evolve, say scientists.

7 Feb 2021

$FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma$

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

5 Feb 2021

FDA continues to support the development of medical products to tackle new virus variants

As the public health agency responsible for regulating medical products, we must ensure that health care providers have the most up-to-date diagnostics, treatments and vaccines in their toolbox to fight this pandemic.

5 Feb 2021

Therapeutics News and Research

Pediatric dietary mobile game improved children’s short-term food choices

Researchers find a way to measure key characteristics of proteins that bind to RNA

Scientists present new outlook on latest trends in peptide drug discovery and development

Exposure to seasonal coronaviruses does not produce antibodies that protect against SARS-CoV-2

Researchers identify top-performing COVID-19 POC tests

MD Anderson and Mirati Therapeutics collaborate to expand evaluation of potent KRAS inhibitors

Modified lipids target the body’s endocannabinoid system to regulate pain and inflammation

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

New study to evaluate the effectiveness of drugs on preventing COVID-19 progression

People with dementia found to have significantly increased risk for COVID-19

New nanoparticle-based drug boosts the body’s innate immune system to fight tumors

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

Study implicates disruption in prenatal neurogenesis in the development of ASDs

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

Could graphene be an effective antiviral platform against SARS-CoV-2?

COVID-19 pandemic and nanotechnology

New SARS-Cov-2 mutations could arise during chronic infection, say scientists

FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma

FDA continues to support the development of medical products to tackle new virus variants

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News